Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$9.37 - $12.12 $603,802 - $781,012
-64,440 Reduced 33.47%
128,116 $1.34 Million
Q1 2021

May 17, 2021

BUY
$10.61 - $15.77 $320,803 - $476,821
30,236 Added 18.63%
192,556 $2.13 Million
Q4 2020

Feb 16, 2021

BUY
$10.21 - $17.31 $984,111 - $1.67 Million
96,387 Added 146.19%
162,320 $1.98 Million
Q3 2020

Nov 16, 2020

SELL
$9.99 - $16.13 $237,841 - $384,023
-23,808 Reduced 26.53%
65,933 $877,000
Q2 2020

Aug 13, 2020

BUY
$11.21 - $18.15 $1.01 Million - $1.63 Million
89,741 New
89,741 $1.35 Million

Others Institutions Holding BYSI

About BeyondSpring Inc.


  • Ticker BYSI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,928,900
  • Market Cap $68.9M
  • Description
  • BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...
More about BYSI
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.